Compare BioNano Genomics Inc (BNGO) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Tenet Healthcare Corporation — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Tenet Healthcare Corporation trades at $183.6 (market cap $15.82B). The key difference: Tenet Healthcare Corporation is far larger — about 1198.5× BioNano Genomics Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | THC | |
|---|---|---|
Market Cap | $13.20M | $15.82B |
Sector | Health | Health |
52-Week High | $4.92 | $244.80 |
52-Week Low | $1.09 | $148.38 |
Enterprise Value | $15.81M | $26.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Tenet Healthcare (THC) trades at $194.81, down 4.62% today, but maintains strong fundamentals with consistent earnings beats and attractive valuation metrics. The stock shows robust profitability with 37.87% ROE and 7.79% net margin, supported by growing outpatient care operations. Technical indicators suggest near-term bearish pressure with key support at $191 and resistance at $198. Recent analyst coverage remains overwhelmingly positive with 81% buy ratings and a $235.88 consensus target.
THC presents a compelling value opportunity with below-market P/E of 9.55 and strong earnings momentum, though technical weakness and upcoming Q2 earnings on July 24 create near-term uncertainty. The expanding ambulatory care segment and defensive healthcare positioning during geopolitical tensions support long-term growth, while debt levels and hospital industry challenges remain key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
